J. Newcomb

发表

Limits of diffusion in the hydrolysis of substrates by the phosphotriesterase from Pseudomonas diminuta.

F. Raushel, S. R. Caldwell, J. Newcomb, 1991, Biochemistry.

Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.

Steve Schneider, Xin Huang, John Newcomb, 2013, Journal of medicinal chemistry.

Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.

David P. Carney, P. Gallant, M. Morrison, 2011, Bioorganic & medicinal chemistry letters.

Characterization of the Loss of SUMO Pathway Function on Cancer Cells and Tumor Proliferation

Xingyue He, J. Newcomb, J. Brownell, 2015, PloS one.

Structure-Based Design of Potent and Selective CK1γ Inhibitors.

H. Bregman, J. Newcomb, Xin Huang, 2012, ACS medicinal chemistry letters.

Invariant chain cleavage and peptide loading in major histocompatibility complex class II vesicles

P. Cresswell, I. Mellman, J. Newcomb, 1995, The Journal of experimental medicine.

Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated alpha beta dimers.

P. Cresswell, J. Newcomb, 1993, Journal of immunology.

Trimeric Interactions of the Invariant Chain and Its Association with Major Histocompatibility Complex Class II αβ Dimers*

P. Cresswell, J. Newcomb, C. Carboy-Newcomb, 1996, The Journal of Biological Chemistry.

Affinity and kinetics of the interactions between an αβ T-cell receptor and its superantigen and class II-MHC/peptide ligands

E. Kawasaki, J. Banerji, J. Newcomb, 1997 .

Requirement for accessory cells in suppression of MOPC-315 IgA secretion by staphylococcal enterotoxin B-induced T-suppressor cells.

J. Newcomb, Y. S. Lin, T. Rogers, 1990, Cellular immunology.

In vitro immunomodulatory activity of ruthenium complexes

K. A. Sterne, J. Newcomb, T. Ocain, 2003, Inflammation Research.

Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.

P. Gallant, A. Oliveira-dos-Santos, J. Newcomb, 2008, Journal of medicinal chemistry.

Effect of isotypic and allotypic variations of MHC class II molecules on staphylococcal enterotoxin presentation to murine T cells.

D. Taub, J. Newcomb, T. Rogers, 1992, Cellular immunology.

Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.

H. Bregman, J. Newcomb, P. Andrews, 2013, Journal of medicinal chemistry.

Production and characterisation of monoclonal antibodies specific for staphylococcal enterotoxin B.

J. Newcomb, Y. S. Lin, T. Rogers, 1988, Journal of medical microbiology.

HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides

P. Cresswell, J. Newcomb, J. Riberdy, 1992, Nature.

Structural analysis of proteolytic products of MHC class II-invariant chain complexes generated in vivo.

P. Cresswell, J. Newcomb, 1993, Journal of immunology.

Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties.

J. Newcomb, Xin Huang, Steve Schneider, 2007, Bioorganic & medicinal chemistry letters.

Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.

P. Gallant, A. Oliveira-dos-Santos, J. Newcomb, 2008, Journal of medicinal chemistry.

Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.

Xin Huang, David Powers, Daniela Metz, 2006, Journal of medicinal chemistry.

N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.

P. Gallant, A. Cheng, J. Newcomb, 2008, Bioorganic & medicinal chemistry letters.

Immunization with soluble BDC 2.5 T cell receptor-immunoglobulin chimeric protein:antibody specificity and protection of nonobese diabetic mice against adoptive transfer of diabetes by maternal immunization

J. Banerji, J. Newcomb, S. Khandekar, 1996, The Journal of experimental medicine.

Immunizat ion with Soluble BDC 2.5 T Cell Receptor-Immunoglobul in Chimeric Protein" Antibody Specificity and Protection o f Nonobese Diabetic Mice against Adoptive Transfer of Diabetes by Maternal Immunizat ion

J. Banerji, J. Newcomb, S. Khandekar, 2022 .

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

S. Tirrell, J. Newcomb, T. Soucy, 2018, Nature Medicine.

Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor.

Pooja Shah, Hua Liao, John Newcomb, 2017, Nature chemical biology.

Mutations in Chlamydomonas reinhardtii Conferring Resistance to the Herbicide Sulfometuron Methyl.

J. Newcomb, R. Hodson, M. E. Hartnett, 1987, Plant physiology.

Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.

L. Toledo, J. Newcomb, D. Stover, 2000, Structure.

The immune response to soluble D10 TCR: analysis of antibody and T cell responses.

J. Banerji, J. Newcomb, S. Khandekar, 1998, International immunology.

Localisation of the mitogenic epitope of staphylococcal enterotoxin B.

J. Newcomb, T. Rogers, M. Binek, 1992, Journal of medical microbiology.

TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells

J. Newcomb, T. Mutis, J. Higgins, 2020 .

Abstract 2384: TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma

J. Newcomb, Anya Lublinsky, C. Harbison, 2019, Immunology.

2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors.

H. Bregman, J. Newcomb, Xin Huang, 2012, Bioorganic & medicinal chemistry letters.

Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR.

A. Cheng, J. Newcomb, Xin Huang, 2007, Bioorganic & medicinal chemistry letters.

Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.

P. Gallant, M. Morrison, D. Elbaum, 2006, Journal of medicinal chemistry.

Affinity and kinetics of the interactions between an alphabeta T-cell receptor and its superantigen and class II-MHC/peptide ligands.

E. Kawasaki, J. Banerji, J. Newcomb, 1997, Molecular immunology.